Mouse Anti-CD47 Recombinant Antibody (clone B6H12.2) (CAT#: PABC-464)

Figure 1 CFSE-labeled AML LSC were incubated with human peripheral blood-derived macrophages (A) or mouse bone marrow-derived macrophages (B) in the presence of IgG1 isotype control, anti-CD45 IgG1, or anti-CD47 (B6H12.2) IgG1 antibody.

These cells were assessed by immunofluorescence microscopy for the presence of fluorescently labeled LSC within the macrophages (indicated by arrows).

Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs Jr, K. D., ... & Weissman, I. L. (2009). CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell, 138(2), 286-299.

Figure 2 The in vitro phagocytosis assay was conducted using mouse macrophages as effector cells.

The phagocytic index (number of target cells ingested per 100 macrophages) was determined for the indicated antibodies.

Chao, M. P., Alizadeh, A. A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., ... & Majeti, R. (2011). Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer research, 71(4), 1374-1384.

Figure 3 (A and B) Flow cytometry plots (A) and quantitation (B) from NOG mice engrafted with lentivirally transduced GFP-positive SU028 AML LSC, 4 hr after treatment with a single 100 mg intraperitoneal dose of anti-CD47 antibody (B6H12.2) or control IgG.

Cell suspensions from bone marrow, spleen, and liver were stained for human CD45 and mouse F4/80, which recognizes phagocytes. All plots are gated on human CD45-negative cells. Double-positive events represent GFP-positive leukemia cells within mouse phagocytes.

Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs Jr, K. D., ... & Weissman, I. L. (2009). CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell, 138(2), 286-299.